Subscribe to RSS
DOI: 10.1055/s-2007-1002053
© Georg Thieme Verlag, Stuttgart · New York
Long-Term Treatment of Central Precocious Puberty with a Long-Acting Analogue of Luteinizing Hormone Release Hormone (D-Tryp6-GnRH) in Monthly Injections
Its Possible Use in Normal PubertyPublication History
1991
1992
Publication Date:
14 March 2008 (online)

Summary
The gonadotropin-releasing-hormone-like agonist D-Tryp6-GnRH (GnRHa) has been shown to induce reversible suppression of gonadotropins and gonadal steroids in patients with central precocious puberty. We examined the effect of a long-acting preparation of GnRHa in biodegradable microcapsules. D-Tryptophane6-GnRH, administered intramuscularly at 1 month intervals, for 12 consecutive months, on growth and skeletal maturation in 3 girls and 4 boys with neurogenic or idiopathic precocious puberty. Suppression of gonadotropin release after GnRH stimulation and gonadal steroids was maintained in all subjets. Growth velocity fell from a mean rate (±SEM) or 8.60±0.75 cm/year before treatment to 5.81±0.60 cm/year (p<0.005) after 1 year. Bone age advanced a mean of 8.0±0.45 months during treatment, suggesting an increase in predicted height from the ratio Δ bone age/Δ chronological age.
Two subjects, one of them with compensated Bartter's syndrome with normal hypothalamic pituitary-gonadal-axis, received the analogue to delay pubertal growth with the hope to improve final height. In the first one, the growth velocity fell from 9.9 cm/year to 8 cm/year and Δ bone age/Δ chronological age decreased from 1.28 to 1.0 and in the other subject, the growth velocity fell from 12 cm/year to 6.0 cm/year in the last year of treatment and Δ bone age/Δ chronological age fell from 3.2 to 0.75, indicating an improvement in predicted height.
Key words
Precocious Puberty - Luteinizing Hormone Releasing-Hormone-Analogue - Treatment